Clinical relevance of host immunity in breast cancer: from TILs to the clinic (original) (raw)

• Underwood, J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br. J. Cancer 30, 538–548 (1974).
  CAS PubMed PubMed Central Google Scholar
• Tsuyuguchi, I., Shiratsuchi, H. & Fukuoka, M. T-lymphocyte subsets in primary lung cancer. Jpn J. Clin. Oncol. 17, 13–17 (1987).
  CAS PubMed Google Scholar
• Sistrunk, W. E. & Maccarty, W. C. Life expectancy following radical amputation for carcinoma of the breast: a clinical and pathologic study of 218 cases. Ann. Surg. 75, 61–69 (1922).
  CAS PubMed PubMed Central Google Scholar
• Tang, R. P. et al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J. Cell. Biochem. 44, 189–198 (1990).
  CAS PubMed Google Scholar
• Whitford, P., George, W. D. & Campbell, A. M. Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. Cancer Lett. 61, 157–164 (1992).
  CAS PubMed Google Scholar
• Chin, Y. et al. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 12, 1463–1466 (1992).
  CAS PubMed Google Scholar
• Schwartzentruber, D. J., Topalian, S. L., Mancini, M. & Rosenberg, S. A. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J. Immunol. 146, 3674–3681 (1991).
  CAS PubMed Google Scholar
• Tanaka, H., Watanabe, M., Zeniya, M. & Takahashi, H. Ultrastructure of IL2-stimulated tumor-infiltrating lymphocytes showing cytolytic activity against tumor cells. Acta Pathol. Jpn 41, 94–105 (1991).
  CAS PubMed Google Scholar
• Schwartzentruber, D. J., Solomon, D., Rosenberg, S. A. & Topalian, S. L. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J. Immunother. 12, 1–12 (1992).
  CAS PubMed Google Scholar
• Baxevanis, C. N. et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74, 1275–1282 (1994).
  CAS PubMed Google Scholar
• Dadmarz, R., Sgagias, M. K., Rosenberg, S. A. & Schwartzentruber, D. J. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol. Immunother. 40, 1–9 (1995).
  CAS PubMed Google Scholar
• Degnim, A. C. et al. Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Res. Treat. 144, 539–549 (2014).
  CAS PubMed PubMed Central Google Scholar
• Gouon-Evans, V., Rothenberg, M. E. & Pollard, J. W. Postnatal mammary gland development requires macrophages and eosinophils. Development 127, 2269–2282 (2000).
  CAS PubMed Google Scholar
• Tuaillon, E. et al. Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. J. Immunol. 182, 7155–7162 (2009).
  CAS PubMed Google Scholar
• Ruffell, B. et al. Leukocyte composition of human breast cancer. Proc. Natl Acad. Sci. USA 109, 2796–2801 (2012).
  CAS PubMed Google Scholar
• Willard-Gallo, K. et al. The significance of tumor infiltrating lymphocyte density, subset composition and organization in breast cancer. [abstract] Cancer Res. 75, aPD1-3 (2015).
  Google Scholar
• Yamaguchi, R. et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum. Pathol. 43, 1688–1694 (2012).
  CAS PubMed Google Scholar
• Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860–867 (2013).
  CAS PubMed Google Scholar
• Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann. Oncol. 25, 1536–1543 (2014).
  CAS PubMed Google Scholar
• Schmidt, M. et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 18, 2695–2703 (2012).
  CAS PubMed Google Scholar
• Ignatiadis, M. et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30, 1996–2004 (2012).
  CAS PubMed Google Scholar
• Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259–271 (2014).
  PubMed PubMed Central Google Scholar
• Gu-Trantien, C. et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013).
  CAS PubMed PubMed Central Google Scholar
• Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105–113 (2010).
  CAS PubMed Google Scholar
• Nawaz, S., Heindl, A., Koelble, K. & Yuan, Y. Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Mod. Pathol. 28, 766–777 (2015).
  CAS PubMed Google Scholar
• Loi, S. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J. Clin. Oncol. 32, 2935–2937 (2014).
  PubMed Google Scholar
• Polley, M.-Y. C. et al. An international Ki67 reproducibility study. J. Natl Cancer Inst. 105, 1897–1906 (2013).
  PubMed PubMed Central Google Scholar
• Van de Pavert, S. A. & Mebius, R. E. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10, 664–674 (2010).
  CAS PubMed Google Scholar
• Brown, M. & Wittwer, C. Flow cytometry: principles and clinical applications in hematology. Clin. Chem. 46, 1221–1229 (2000).
  CAS PubMed Google Scholar
• Stack, E. C., Wang, C., Roman, K. A. & Hoyt, C. C. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70, 46–58 (2014).
  CAS PubMed Google Scholar
• Denkert, C. et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 33, 983–991 (2015).
  CAS PubMed Google Scholar
• Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
  CAS PubMed PubMed Central Google Scholar
• Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 (2014).
  PubMed Google Scholar
• Tan, M. C. et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am. J. Surg. 198, 520–525 (2009).
  PubMed PubMed Central Google Scholar
• Kraus, J. A. et al. Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 20, 334–339 (2012).
  CAS PubMed Google Scholar
• Kurozumi, S. et al. ER, PgR, Ki67, 27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide conco. BMC Cancer 15, 622 (2015).
  PubMed PubMed Central Google Scholar
• Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101, 1446–1452 (2009).
  PubMed PubMed Central Google Scholar
• Loi, S. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25, 1544–1550 (2014).
  CAS PubMed Google Scholar
• Adams, S. et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32, 2959–2966 (2014).
  PubMed PubMed Central Google Scholar
• Salgado, R. et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab. JAMA Oncol. 1, 448 (2015).
  PubMed PubMed Central Google Scholar
• Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2007).
  CAS PubMed Google Scholar
• Mattarollo, S. R. et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71, 4809–4820 (2011).
  CAS PubMed Google Scholar
• Issa-Nummer, Y. et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer — a substudy of the neoadjuvant GeparQuinto trial. PLoS ONE 8, e79775 (2013).
  PubMed PubMed Central Google Scholar
• West, N. R. et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 13, R126 (2011).
  CAS PubMed PubMed Central Google Scholar
• Dieci, M. et al. Tumor infiltrating lymphocytes and correlation with outcome in the Cher-LOB study. [abstract] Cancer Res. 75, aPD1-1 (2015).
  Google Scholar
• Loi, S. et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). [abstract] Cancer Res. 73, aS1-05 (2013).
  Google Scholar
• Demaria, S. et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 7, 3025–3030 (2001).
  CAS PubMed Google Scholar
• Horlock, C. et al. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br. J. Cancer 100, 1061–1067 (2009).
  CAS PubMed PubMed Central Google Scholar
• Ladoire, S. et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin. Cancer Res. 14, 2413–2420 (2008).
  CAS PubMed Google Scholar
• Dieci, M. V. et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann. Oncol. 25, 1–8 (2014).
  Google Scholar
• Loi, S. et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple- negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-15-1125 (2015).
• García-Martínez, E. et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 16, 488 (2014).
  PubMed PubMed Central Google Scholar
• Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747–752 (2013).
  CAS PubMed PubMed Central Google Scholar
• Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81–85 (2014).
  PubMed Google Scholar
• Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
  CAS PubMed PubMed Central Google Scholar
• Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
  CAS PubMed Google Scholar
• Rajasagi, M. et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124, 453–462 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 1–15 (2014).
  Google Scholar
• Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572–576 (2014).
  CAS PubMed Google Scholar
• Granados, D. P. et al. Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nat. Commun. 5, 3600 (2014).
  PubMed Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
• Denizot, F., Wilson, A., Battye, F., Berke, G. & Shortman, K. Clonal expansion of T cells: a cytotoxic T-cell response in vivo that involves precursor cell proliferation. Proc. Natl Acad. Sci. USA 83, 6089–6092 (1986).
  CAS PubMed PubMed Central Google Scholar
• Langhoff, E. & Steinman, R. M. Clonal expansion of human T lymphocytes initiated by dendritic cells. J. Exp. Med. 169, 315–320 (1989).
  CAS PubMed Google Scholar
• Marchingo, J. M. et al. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion. Science 346, 1123–1127 (2014).
  CAS PubMed Google Scholar
• Mlecnik, B. et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 6, 228ra37 (2014).
  PubMed Google Scholar
• Ye, J. et al. Specific recruitment of γδ regulatory T cells in human breast cancer. Cancer Res. 73, 6137–6148 (2013).
  CAS PubMed PubMed Central Google Scholar
• Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
  CAS PubMed PubMed Central Google Scholar
• Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).
  CAS PubMed PubMed Central Google Scholar
• Woo, S.-R. et al. The STING pathway mediates innate immune sensing of immunogenic tumors. Immunity 41, 830–842 (2014).
  CAS PubMed PubMed Central Google Scholar
• Hansen, M. H., Nielsen, H. V. & Ditzel, H. J. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J. Immunol. 169, 2701–2711 (2002).
  CAS PubMed Google Scholar
• Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73 (2008).
  CAS PubMed Google Scholar
• Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
  CAS PubMed Google Scholar
• Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
  CAS PubMed Google Scholar
• Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).
  PubMed PubMed Central Google Scholar
• Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).
  CAS PubMed PubMed Central Google Scholar
• Read, S., Malmström, V. & Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295–302 (2000).
  CAS PubMed PubMed Central Google Scholar
• Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).
  CAS PubMed Google Scholar
• Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
  CAS PubMed Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
  CAS PubMed PubMed Central Google Scholar
• Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
  CAS PubMed Google Scholar
• Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
  CAS PubMed Google Scholar
• Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
  CAS PubMed PubMed Central Google Scholar
• Schalper, K. A. et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin. Cancer Res. 20, 2773–2782 (2014).
  CAS PubMed Google Scholar
• Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607–615 (2014).
  CAS PubMed PubMed Central Google Scholar
• Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171–6180 (2010).
  CAS PubMed PubMed Central Google Scholar
• Gramaglia, I., Weinberg, A. D., Lemon, M. & Croft, M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161, 6510–6517 (1998).
  CAS PubMed Google Scholar
• Vu, M. D. et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 110, 2501–2510 (2007).
  CAS PubMed PubMed Central Google Scholar
• Ruby, C. E. et al. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J. Immunol. 183, 4853–4857 (2009).
  CAS PubMed Google Scholar
• Curti, B. D. et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189–7198 (2013).
  CAS PubMed PubMed Central Google Scholar
• Monney, L. et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536–541 (2002).
  CAS PubMed Google Scholar
• Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).
  CAS PubMed PubMed Central Google Scholar
• Ngiow, S. F. et al. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71, 3540–3551 (2011).
  CAS PubMed Google Scholar
• Sakuishi, K. et al. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2, e23849 (2013).
  PubMed PubMed Central Google Scholar
• Huang, Y.-H. et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517, 386–390 (2014).
  PubMed PubMed Central Google Scholar
• Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P. & Munn, D. H. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol. 168, 3771–3776 (2002).
  CAS PubMed Google Scholar
• Qian, F. et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 69, 5498–5504 (2009).
  CAS PubMed Google Scholar
• US National Library of Medicine. NCT01792050. ClinicalTrials.gov [online], (2015).
• US National Library of Medicine. NCT02048709. ClinicalTrials.gov [online], (2015).
• Antonioli, L., Blandizzi, C., Pacher, P. & Haskó, G. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13, 842–857 (2013).
  CAS PubMed Google Scholar
• Loi, S. et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl Acad. Sci. USA 110, 11091–11096 (2013).
  CAS PubMed PubMed Central Google Scholar
• Stagg, J. et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107, 1547–1552 (2010).
  CAS PubMed PubMed Central Google Scholar
• Beavis, P. A. et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl Acad. Sci. USA 110, 14711–14716 (2013).
  CAS PubMed PubMed Central Google Scholar
• Beavis, P. A. et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res. 3, 506–517 (2015).
  CAS PubMed Google Scholar
• Hauser, R. A. et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 13, 767–776 (2014).
  CAS PubMed Google Scholar
• Emens, L. et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. [abstract] Cancer Res. 75, aPD1-6 (2015).
  Google Scholar
• Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009).
  CAS PubMed Google Scholar
• US National Library of Medicine. NCT02425891. ClinicalTrials.gov [online], (2015).
• Nanda, R. et al. A Phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. [abstract] Cancer Res. 75, aS1-09 (2015).
  Google Scholar
• US National Library of Medicine. NCT02447003. ClinicalTrials.gov [online], (2015).
• Vonderheide, R. H. et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16, 3485–3494 (2010).
  CAS PubMed Google Scholar
• Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
  CAS PubMed PubMed Central Google Scholar
• Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142–7147 (2011).
  CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. NCT02129556. ClinicalTrials.gov [online], (2015).
• Verbrugge, I. et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72, 3163–3174 (2012).
  CAS PubMed Google Scholar
• Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379–5388 (2009).
  CAS PubMed PubMed Central Google Scholar
• Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
  CAS PubMed Google Scholar
• US National Library of Medicine. NCT02303366. ClinicalTrials.gov [online], (2015).
• Eggermont, A. M. et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. [abstract] J. Clin. Oncol. 32, aLBA9008 (2014).
  Google Scholar
• Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
  CAS PubMed PubMed Central Google Scholar
• Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
  CAS PubMed PubMed Central Google Scholar
• Velcheti, V. et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Invest. 94, 107–116 (2014).
  CAS PubMed Google Scholar
• Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
  PubMed PubMed Central Google Scholar
• Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
  CAS PubMed Google Scholar
• Quezada, S. A. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205, 2125–2138 (2008).
  CAS PubMed PubMed Central Google Scholar
• Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  CAS PubMed PubMed Central Google Scholar
• Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
  CAS PubMed PubMed Central Google Scholar
• Savas, P. S. et al. Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). [abstract] J. Clin. Oncol. 33, a613 (2015).
  Google Scholar
• Cimino-Mathews, A., Ye, X., Meeker, A., Argani, P. & Emens, L. A. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum. Pathol. 44, 2055–2063 (2013).
  PubMed PubMed Central Google Scholar
• Kawai, O. et al. Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113, 1387–1395 (2008).
  CAS PubMed Google Scholar
• Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015).
  CAS PubMed Google Scholar